Tag Archives: guinea pigging

Guinea pigging and a walk down memory lane for Remembrance Day 2024

While this isn’t one of my usual areas of interest, there is a personal element for me (more about that at the end). Some people earn their living as subjects for drug tests; it’s called guinea pigging. (There’s more here in a July 1, 2015 posting; see the first three paragraphs after the information about cross-posting and the circumstances under which I wrote the article.)

Earlier this fall (2024), the Canadian Broadcasting Corporation (CBC) released a documentary, Bodies for Rent, focusing on two guinea piggers. Here’s more from a September 25, 2024 CBC online article about their documentary,

Before a drug becomes available on the market, it must undergo rigorous testing and multiple levels of clinical trials to ensure its functionality and safety. Every year, thousands of people in Canada and the U.S. take part in these trials, and may receive financial compensation for doing so. 

A new documentary highlights how some volunteers are attempting to earn a living by putting their bodies on the line. Bodies for Rent follows two men who spend their days searching for eligible clinical studies, and shows the lengths they’ll go to in order to complete a trial and get paid.  

A way to make a ‘living’

Participating in a trial for a medical drug still under development involves reporting any side effects. It’s a potentially dangerous “job,” but for many volunteers, the rewards outweigh the risks. 

“I think I’ve done more than 40 studies,” says 55-year-old “Franco,” who conceals his real identity with makeup in the documentary. “I was struggling to pay my rent. And I saw an ad at the subway in Toronto, and they said, ‘Would you like to make up to $1,200 over a weekend?'”

“I usually make [$30,000] to 40,000 a year. Before, I was making, like, $18,000 working at a factory.”

Raighne, an artist living in Minneapolis, was raised by a single mother and grew up on welfare. “I’ve done about 20 or 30 drug trials,” he says in the film. “And nothing makes money like clinical studies.”

Trying to get out of debt and manage an unstable business, Raighne sometimes spends days or weeks away from home while participating in a study. “I had a friend describe it as, like, ‘drug jail,'” he says. “Because you’re trapped for a set amount of time. You’re under observation.”

From testing on prisoners to testing on the poor

Before the 1970s, most Phase I clinical trials — which look at a drug’s safety, determine the safe dosage range and see if there are any side effects — were conducted on prisoners. This allowed researchers to control and monitor every aspect of participants’ lives. 

“These studies did the most unimaginably horrible things you can think of to prisoners there,” says Carl Elliott, a University of Minnesota bioethicist featured in Bodies for Rent and the author of The Occasional Human Sacrifice: Medical Experimentation and the Price of Saying No [emphasis mine]. 

“For example, they injected inmates with herpes. They injected them with asbestos. They even tested chemical warfare agents on them.”

Public outcry and new reforms eventually made research in prisons much more difficult. “The question was, ‘Well, who do we do Phase I trials on now?’ We can’t do them on prisoners anymore,” says Elliott. 

“The answer is poor people.”

‘A financial incentive to lie’

When testing in prisons stopped and financial incentives were introduced, students and people impacted by poverty became more common test subjects. However, the promise of money at the completion of a trial has added complications. 

“When I started doing studies, I used to be very honest,” says Franco. “I [would] tell all the side effects that I was going through.” 

But after reporting severe migraines during one study, Franco says he was forced to leave — with less than 20 per cent of the promised payout. He says he was also blocked from doing further studies with that company. 

“I [was] being penalized for being honest. So, after that, I kind of learned my lesson and I decided to tone down the side effects,” he says. 

Once in a study, the risks persist. Franco says that after participating for nearly two months in a study worth around $20,000 to him, he received a call from the clinic saying he had inflammation in his pancreas. The study manager told him he was being removed from the study, and later, the clinic advised him to go to an emergency room immediately. 

“I hope it’s not permanent. If it’s permanent, then I’m gonna be upset,” Franco says to the camera in the documentary. “I was supposed to get around $20,000. If I don’t get the full amount because I am getting side effects, I think that it’s unfair.”

In the end, Franco was paid $9,000. 

The September 25, 2024 CBC online article also includes an embedded video about testing on prisoners. “Bodies for Rent” can be viewed on CBC Gem. (You do have to create an account in order to view the documentary or anything else on CBC Gem.)

A walk down memory lane for Remembrance Day 2024

When my father was in basic training for the Canadian army and preparing to fight in World War II, he participated in some kind of experiment. The details are fuzzy as he didn’t talk about it much but he did insist that some of his medical problems (specifically, the problems he had with his skin) were directly due to his experience as a guinea pig and that he should be compensated by the Canadian government. If memory serves, he felt the army had misled him into participating in the experiment. .

Papa was 15 1/2 when he lied his way into the army. Not too long after, the army realizing its mistake kept him back from the front (in some training camp in the Prairies), which is when he became a medical experiment for a time. On reaching the age of 18 the Canadian army shipped him overseas.

When he finally did try to speak up about his experience as a guinea pig it was the late 1960s and he didn’t pursue the matter for long being of the opinion that no one would pay much attention. He wasn’t wrong.

It wasn’t until details about the infamous Tuskegee Syphilis Study were revealed that there was serious discussion about informed consent (about 1972) in the United States. I don’t know when it became a serious discussion in Canada. Even then, some of the research from the 1970s is stomach churning as I found on stumbling across a study from that period. The researchers were conducting an experiment with a drug they knew was not going to work and that had bad side effects as was noted in the abstract. The testing took place on patients in a hospital ward.

There is still a long ways to go as evidenced by the “Bodies for Rent” documentary and Elliott’s 2024 book “The Occasional Human Sacrifice: Medical Experimentation and the Price of Saying No”. I hope there are changes to how drug testing is done as a consequence of added awareness but it’s a long hard road to change.

For my father on Remembrance Day 2024: you were right; what they did to you was wrong. And still, you went and fought. Thank you.

A pragmatic approach to alternatives to animal testing

Retitled and cross-posted from the June 30, 2015 posting (Testing times: the future of animal alternatives) on the International Innovation blog (a CORDIS-listed project dissemination partner for FP7 and H2020 projects).

Maryse de la Giroday explains how emerging innovations can provide much-needed alternatives to animal testing. She also shares highlights of the 9th World Congress on Alternatives to Animal Testing.

‘Guinea pigging’ is the practice of testing drugs that have passed in vitro and in vivo tests on healthy humans in a Phase I clinical trial. In fact, healthy humans can make quite a bit of money as guinea pigs. The practice is sufficiently well-entrenched that there is a magazine, Guinea Pig Zero, devoted to professionals. While most participants anticipate some unpleasant side effects, guinea pigging can sometimes be a dangerous ‘profession’.

HARMFUL TO HEALTH

One infamous incident highlighting the dangers of guinea pigging occurred in 2006 at Northwick Park Hospital outside London. Volunteers were offered £2,000 to participate in a Phase I clinical trial to test a prospective treatment – a monoclonal antibody designed for rheumatoid arthritis and multiple sclerosis. The drug, called TGN1412, caused catastrophic systemic organ failure in participants. All six individuals receiving the drug required hospital treatment. One participant reportedly underwent amputation of fingers and toes. Another reacted with symptoms comparable to John Merrick, the Elephant Man.

The root of the disaster lay in subtle immune system differences between humans and cynomolgus monkeys – the model animal tested prior to the clinical trial. The drug was designed for the CD28 receptor on T cells. The monkeys’ receptors closely resemble those found in humans. However, unlike these monkeys, humans have other immune cells that carry CD28. The trial participants received a starting dosage that was 0.2 per cent of what the monkeys received in their final tests, but failure to take these additional receptors into account meant a dosage that was supposed to occupy 10 per cent of the available CD28 receptors instead occupied 90 per cent. After the event, a Russian inventor purchased the commercial rights to the drug and renamed it TAB08. It has been further developed by Russian company, TheraMAB, and TAB08 is reportedly in Phase II clinical trials.

HUMAN-ON-A-CHIP AND ORGANOID PROJECTS

While animal testing has been a powerful and useful tool for determining safe usage for pharmaceuticals and other types of chemicals, it is also a cruel and imperfect practice. Moreover, it typically only predicts 30-60 per cent of human responses to new drugs. Nanotechnology and other emerging innovations present possibilities for reducing, and in some cases eliminating, the use of animal models.

People for the Ethical Treatment of Animals (PETA), still better known for its publicity stunts, maintains a webpage outlining a number of alternatives including in silico testing (computer modelling), and, perhaps most interestingly, human-on-a-chip and organoid (tissue engineering) projects.

Organ-on-a-chip projects use stem cells to create human tissues that replicate the functions of human organs. Discussions about human-on-a-chip activities – a phrase used to describe 10 interlinked organ chips – were a highlight of the 9th World Congress on Alternatives to Animal Testing held in Prague, Czech Republic, last year. One project highlighted at the event was a joint US National Institutes of Health (NIH), US Food and Drug Administration (FDA) and US Defense Advanced Research Projects Agency (DARPA) project led by Dan Tagle that claimed it would develop functioning human-on-a-chip by 2017. However, he and his team were surprisingly close-mouthed and provided few details making it difficult to assess how close they are to achieving their goal.

By contrast, Uwe Marx – Leader of the ‘Multi-Organ-Chip’ programme in the Institute of Biotechnology at the Technical University of Berlin and Scientific Founder of TissUse, a human-on-a-chip start-up company – claims to have sold two-organ chips. He also claims to have successfully developed a four-organ chip and that he is on his way to building a human-on-a-chip. Though these chips remain to be seen, if they are, they will integrate microfluidics, cultured cells and materials patterned at the nanoscale to mimic various organs, and will allow chemical testing in an environment that somewhat mirrors a human.

Another interesting alternative for animal testing is organoids – a feature in regenerative medicine that can function as test sites. Engineers based at Cornell University recently published a paper on their functional, synthetic immune organ. Inspired by the lymph node, the organoid is comprised of gelatin-based biomaterials, which are reinforced with silicate nanoparticles (to keep the tissue from melting when reaching body temperature) and seeded with cells allowing it to mimic the anatomical microenvironment of a lymphatic node. It behaves like its inspiration converting B cells to germinal centres which activate, mature and mutate antibody genes when the body is under attack. The engineers claim to be able to control the immune response and to outperform 2D cultures with their 3D organoid. If the results are reproducible, the organoid could be used to develop new therapeutics.

Maryse de la Giroday is a science communications consultant and writer.

Full disclosure: Maryse de la Giroday received transportation and accommodation for the 9th World Congress on Alternatives to Animal Testing from SEURAT-1, a European Union project, making scientific inquiries to facilitate the transition to animal testing alternatives, where possible.

ETA July 1, 2015: I would like to acknowledge more sources for the information in this article,

Sources:

The guinea pigging term, the ‘professional aspect, the Northwick Park story, and the Guinea Pig Zero magazine can be found in Carl Elliot’s excellent 2006 story titled ‘Guinea-Pigging’ for New Yorker magazine.

http://www.newyorker.com/magazine/2008/01/07/guinea-pigging

Information about the drug used in the Northwick Park Hospital disaster, the sale of the rights to a Russian inventor, and the June 2015 date for the current Phase II clinical trials were found in this Wikipedia essay titled, TGN 1412.

http://en.wikipedia.org/wiki/TGN1412

Additional information about the renamed drug, TAB08 and its Phase II clinical trials was found on (a) a US government website for information on clinical trials, (b) in a Dec. 2014 (?) TheraMAB  advertisement in a Nature group magazine and a Jan. 2014 press release,

https://www.clinicaltrials.gov/ct2/show/NCT01990157?term=TAB08_RA01&rank=1

http://www.theramab.ru/TheraMAB_NAture.pdf

http://theramab.ru/en/news/phase_II

An April 2015 article (Experimental drug that injured UK volunteers resumes in human trials) by Owen Dyer for the British Medical Journal also mentioned the 2015 TheraMab Phase II clinical trials and provided information about the information about Macaque (cynomolgus) monkey tests.

http://www.bmj.com.proxy.lib.sfu.ca/content/350/bmj.h1831

BMJ 2015; 350 doi: http://dx.doi.org.proxy.lib.sfu.ca/10.1136/bmj.h1831 (Published 02 April 2015) Cite this as: BMJ 2015;350:h1831

A 2009 study by Christopher Horvath and Mark Milton somewhat contradicts the Dyer article’s contention that a species Macaque monkey was used as an animal model. (As the Dyer article is more recent and the Horvath/Milton analysis is more complex covering TGN 1412 in the context of other MAB drugs and their precursor tests along with specific TGN 1412 tests, I opted for the simple description.)

The TeGenero Incident [another name for the Northwick Park Accident] and the Duff Report Conclusions: A Series of Unfortunate Events or an Avoidable Event? by Christopher J. Horvath and Mark N. Milton. Published online before print February 24, 2009, doi: 10.1177/0192623309332986 Toxicol Pathol April 2009 vol. 37 no. 3 372-383

http://tpx.sagepub.com/content/37/3/372.full

Philippa Roxbuy’s May 24, 2013 BBC news online article provided confirmation and an additional detail or two about the Northwick Park Hospital accident. It notes that other models, in addition to animal models, are being developed.

http://www.bbc.com/news/health-22556736

Anne Ju’s excellent June 10,2015 news release about the Cornell University organoid (synthetic immune organ) project was very helpful.

http://www.news.cornell.edu/stories/2015/06/engineers-synthetic-immune-organ-produces-antibodies

There will also be a magazine article in International Innovation, which will differ somewhat from the blog posting, due to editorial style and other requirements.

ETA July 22, 2015: I now have a link to the magazine article.